 |
인쇄하기
취소
|
Ildong to market Shionogi’s pirfenidone in Korea
Ildong Pharmaceutical said Tuesday that it entered into a licensing agreement with Shionogi & Co., Ltd. on May 30 for the sale of pirfenidone in Korea on an exclusive basis.
Following the execution of agreement, Ildong will file a New Drug Application and exclusively sell this product in Korea.
Pirfenidone is a promising therapeutic agent which is expected to inhibit the progression of id...
Following the execution of agreement, Ildong will file a New Drug Application and exclusively sell this product in Korea.
Pirfenidone is a promising therapeutic agent which is expected to inhibit the progression of id...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.